US 2013/0158077 A1Published application

Pharmaceutical compositions

AssigneeAres Trading S.A.

InventorBJOERN C. KAHRS

Life of this patent

Estimating the term…

Abstract

The invention relates to pharmaceutical compositions comprising PPAR agonists and Nrf2 activators and methods of using combinations of PPAR agonists and Nrf2 activators for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis.

Claims12

Dependent claims

A method of treating multiple sclerosis or clinically isolated syndrome (CIS) comprising the administration of a pharmaceutical composition comprising a glitazone and a fumaric acid monoalkyl ester and/or fumaric acid dialkyl ester to a patient having multiple sclerosis or clinically isolated syndrome.

Dependencies are inferred from the claim text.

Facts

Application: 13/654,632Filed 18 Oct 2012
Priority: EP 11194292.619 Dec 2011
Published: 20 Jun 2013
Term ends: Not estimatedThe source records don’t support an estimate.

Classification33 codes

A61K 31/4439
Containing further heterocyclic ring systems: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 9/0053
Galenical forms characterised by the site of application: mouth and digestive tract, i.e. intraoral and peroral administration
A61K 31/12
Medicinal preparations containing organic active ingredients: ketones
A61K 31/16
Medicinal preparations containing organic active ingredients: amides, e.g. hydroxamic acids

Family

Application61/663,761Us provisional application · filed 25 Jun 2012
US 2013/0158077 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key

patentgrep

Loading patent…

patentgrepSearch patents

Back to results